Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | NNMT | P40261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343084 | 0.81 | MKNK1 (0.39) | MAPK14TSHRMAP2K2MAP2K1RIPK2 | |
| SCHEMBL3346920 | 0.76 | RAB9A (0.45) | NNMTTSHRRIPK2ALDH1A1LMNA | |
| SCHEMBL1225829 | 0.70 | — | — | |
| SCHEMBL2182734 | 0.69 | DGAT1 (0.44) | NNMTTSHRMAP2K2MAP2K1ALDH1A1 | |
| SCHEMBL8042666 | 0.69 | RIPK2 (0.49) | MAPK14TSHRRIPK2LMNARAB9A | |
| SCHEMBL32691671 | 0.67 | TSHR (0.51) | TSHRALDH1A1TTRLMNASMN1; SMN2 | |
| SCHEMBL3342413 | 0.65 | MKNK2 (0.39) | NNMTRIPK2ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2858381 | 0.65 | DGAT1 (0.40) | NNMTSIRT3TDP1 | |
| SCHEMBL8154315 | 0.65 | DGAT1 (0.40) | NNMTTSHRMAP2K2MAP2K1ALDH1A1 | |
| SCHEMBL12506847 | 0.64 | DGAT1 (0.42) | NNMTTSHRMAP2K2MAP2K1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX6, P2RX3 | MAPK14 3280/4885NNMT 1340/4885TSHR 1051/4885 |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | MAPK14 2454/4885NNMT 1340/4885TSHR 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.